DSP-3025
Phase 1Small molecule
DSP-3025 is one of 33 small molecule programs targeting Seasonal Allergic Rhinitis. It is currently in Phase 1.
1
Indications
2
Total Trials
0
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
122 competitors in Seasonal Allergic Rhinitis
#DrugCompanyPhaseTrials
1Alvesco
AAzurity Pharmaceuticals
Phase 3
Xolair
RochePhase 3
Qvar
SSchering-Plough
Phase 3
Sudafed
KKenvue Brands
Phase 3
Bilaxten
MMenarini International Operations Luxembourg SA
Phase 3
Comparator: Statins
Merck & Co.Phase 3
Neo-Synephrine
EExela Pharma Sciences, LLC.
Phase 3
REGN5713
RegeneronPhase 3
REGN5715
RegeneronPhase 3
GW685698X
GSKPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DSP-3025. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SSumitomo Pharma Co., Ltd.